AYTU
has been under pressure forever with the 50 DMA being the strongest level of resistance over the last few months. However, if you take the chart waaayyyyy out, you'll see that it's bouncing off of a historic level of support, which was confirmed after this latest move. Yet again the 50DMA denied the rally even with higher volume. The company has an upcoming presentation at the Raymond James Human Health Innovations Conference on June 23rd. "Since its inception, AYTU has evolved into an acquisition-based company that puts a priority on strategic in-licensing. It also has a strong drug development pipeline that focuses on rare genetic diseases called vascular Ehlers-Danlos Syndrome (vEDS). Currently, it’s testing a potential treatment – AR101/enzastaurin, in an attempt to reduce morbidity and lengthen life. While testing can take a substantial amount of time, having a steady flow of research in a pipeline is always encouraging for biotech investors to see."
Quote Source: 7 Top Penny Stocks to Watch Right Now With Big News